

REMARKS

Claims 1-47 are pending in the present application. Claims 33 and 35-47 are withdrawn from consideration as drawn to a non-elected invention. Claims 1-32 and 34 are objected to as containing non-elected subject matter. Applicants are herein amending claims 1 and 2 to cancel restricted subject matter and canceling claims 23-32 as drawn to non-elected inventions. Applicants reserve the right to pursue the canceled subject matter in continuing applications. Applicants are also making claims 9, 14, and 20 independent and amending claims 16 and 19 for purposes of improved clarity. The amendments to claims 16 and 19 are supported, for example, on pages 26-30 of the application. Applicants request that claims 33 and 35-47 be rejoined in accordance with M.P.E.P. 821.04 which states that if applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims, which depend from or otherwise include all of the limitations of the allowable product claims will be rejoined.

In order to aid the Examiner with the examination of claims 33 and 35-47, Applicants are herein providing literature references that describe the correlation between plasmin, PAI-1 activity and at least one of the various diseases or conditions set forth in claims 33 and 35-47. As set forth in the background of the specification, elevated levels of PAI-1 have been associated with a variety of diseases and conditions including those associated with impairment of the fibrinolytic system. The table below summarizes literature references that describe the correlation between plasmin, PAI-1 activity and at least one of the various diseases or conditions set forth in claims 33 and 35-47. Applicants are providing herewith copies of the abstract and/or entire journal article for those references not previously provided to the Office.

Condition	Reference
Thrombotic diseases	Krishnamurti, <i>Blood</i> , 69: 798 (1987); Reilly, <i>Arteriosclerosis and Thrombosis</i> , 11, 1276 (1991); Carmeliet, <i>Journal of Clinical Investigation</i> , 92: 2756 (1993); Rocha, <i>Fibrinolysis</i> , 8: 294 (1994); Aznar, <i>Haemostasis</i> 24: 243 (1994); Biemond, <i>Circulation</i> , 91: 1175 (1995);

Condition	Reference
	Levi, <i>Circulation</i> 85: 305 (1992)
Cardiovascular disease	Takazoe <i>et. al</i> , <i>Ann Med</i> 33: 206-212 (2001); Wind <i>et al.</i> , <i>Eur. J. Biochem.</i> 268: 1095-1106 (2001)
Myocardial infarction	Thogersen <i>et. al</i> , <i>Circulation</i> 98:2241-2247 (1998)
Atherosclerosis	Schneiderman J. <i>et. al</i> , <i>Proc Natl Acad Sci</i> 89: 6998-7002 (1992); Sobel, <i>Proceedings of the Association of American Physicians</i> 111(4): 313-318 (1999)
Atrial fibrillation	Roldan <i>et al.</i> , <i>American Heart Journal</i> , 136(6): 956-960 (1998)
Stroke	Albers, <i>Neurology</i> , 57(suppl 2):S77-S81 (2001)
Deep vein thrombosis	Juhan-Vague I, <i>et. al</i> , <i>Thromb Haemost</i> 57: 67-72 (1987)
Venous and arterial thrombosis	Berry <i>et al.</i> , <i>British Journal of Pharmacology</i> 125: 29-34 (1998)
Diabetes	Juhan-Vague I, <i>et. al</i> , <i>Thromb Haemost</i> 78: 565-660, (1997); Malamas, M. S. <i>et al.</i> , <i>J. Med. Chem.</i> , 43:995-1010 (2000); Malamas, M. S. <i>et al.</i> , <i>Eur. J. Med. Chem.</i> , 36:31-42 (2001); Takanashi and Inukai, <i>Journal of Medicine</i> , Vol. 31, Nos 1 & 2: 45-62; (2000)
Glomerulonephritis	Hamano <i>et al.</i> , <i>American Journal of Kidney Diseases</i> 39(4): 695-705 (2002)
Renal failure	Lahlou <i>et al.</i> , <i>Transplantation</i> 73: 1290-1295 (2003)
Chronic obstructive pulmonary disease	Ashitani <i>et al.</i> , <i>Internal Medicine</i> , 41(3): 181-185 (2002)
Arterial and venous thrombi, contributing respectively to coronary arterial occlusion in post-myocardial infarction	Hamsten A, <i>et. al. Lancet</i> 2:3-9 (1987)
Venous thrombosis following post-operative recovery from orthopedic surgery	Siemens HJ, <i>et. al</i> , <i>J Clin Anesthesia</i> 11: 622-629 (1999)
Cardiovascular disease in post-menopausal women	Koh K <i>et. al</i> , <i>N Engl J Med</i> 336: 683-690 (1997)
Polycystic ovary syndrome	Atiomo <i>et al.</i> , <i>Gynecol Endocrinol</i> , 14:162-168 (2000); Glueck <i>et al.</i> , <i>Fertility and Sterility</i> , 75(1): 46-52 (2001); Nordt, <i>Journal of clinical Endocrinology and Metabolism</i> , 85(4): 1563 (2000)
Bone loss induced by estrogen deficiency	Daci, <i>Journal of Bone and Mineral Research</i> , 15(8): 1510 (2000)

Condition	Reference
Alzheimer's disease	<p>Periz and Fortini, <i>EMBO Reports</i>, 1:477-478, (2000); Tucker et al. <i>J. Neurosci.</i> 20:3937-3946 (2000); Kingston et al. <i>Nat. Med.</i> 1:138-142 (1995); Wnendt et al. <i>Thromb. Res.</i> 8:217-224 (1997); Van Nostrand and Porter, <i>Biochemistry</i> 38:11570-11576 (1999); Exley and Korchazhkina, <i>Neuroreport.</i> 12:2967-2970 (2001); Tucker et al. <i>J. Neurochem.</i> 75:2172-2177 (2000); Tsirka et al. <i>J. Neurosci.</i> 17:543-552 (1997); Seeds et al. <i>PNAS</i>, 96:14118-14123 (1999); McGeer and McGeer, <i>Brain Res. Rev.</i> 21:195-218 (1995); Ledesma et al. <i>EMBO Reports</i>, 1:530-535 (2000); Simons et al. <i>PNAS</i> 95:6460-6464 (1998); Melchor et al. <i>J. Neurosci.</i> 23:8867-8871 (2003); Tucker et al. <i>J. Neurosci. Res.</i> 70:249-255 (2002); Kim et al. <i>Science</i>, 284:647-650 (1999); Fay et al. <i>Blood</i> 90:204-208 (1997); Carmeliet et al. <i>Ann. NY Acad Sci</i>, 748:367-381 (1995);</p>
Cancer	<p>Frandsen et al., <i>Drugs of the Future</i> 23(8): 873-883 (1998); Isogai, et al., <i>Cancer Research</i> 61(14): 5587-5594 (2001); Qu et al., <i>Zhongliu Fangzhi Zazhi</i> 10(8): 821-824 (2003); Look et al., <i>Journal of the National Cancer Institute</i> 94(2): 116-128 (2002); Chazaud et al., <i>American Journal of Pathology</i> 160(1): 237-246 (2002); Egelund et al., <i>Journal of Biological Chemistry</i> 276(16): 13077-13086 (2001); Wind et al., <i>European Journal of Biochemistry</i> 268(4): 1095-1106 (2001); Bianchi et al., <i>International Journal of Cancer</i> 60(5): 597-603 (1995); Zhao et al., <i>Breast cancer</i> (Tokyo, Japan) 9(2): 118-26 (2002)</p>

DOCKET NO.: AM100637 (WYNC-1031)


PATENT

Application No.: 10/731,308

Office Action Dated: July 5, 2006

Applicants respectfully submit that the present application is in condition for allowance. If the Examiner believes that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided. Favorable consideration and an early notice of allowance are respectfully requested.

Date: October 4, 2006



Leslie E. Aberman
Registration No. 54,836

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439